(Anti-HER2 antibody)-drug conjugate
As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L 1 -L 2 -L P -NH—(CH 2 )n 1 -L a -L b -L c or -L 1 -L 2 -L P - wherein the anti-HER2 antibody is connected to the terminal L 1 , and the antitumor compound is connected to the terminal L c or L P with the nitrogen atom of the amino group at position 1 as the connecting position.
1. An antibody-drug conjugate wherein an antitumor compound represented by the following formula:
is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula:
-L 1 -L 2 -L P -
wherein
the anti-HER2 antibody is connected to the terminal L 1 , the antitumor compound is connected to the terminal L c or L P with the nitrogen atom of the amino group at position 1 as the connecting position,
wherein
n 1 represents an integer of 0 to 6,
L 1 represents -(Succinimid-3-yl-N)—(CH 2 )n 2 -C(═O)—,
wherein n 2 represents an integer of 2 to 8,
L 2 represents —NH—(CH 2 CH 2 —O)n 6 -CH 2 CH 2 —C(═O)— or a single bond,
wherein n 6 represents an integer of 0 to 6,
L P represents a peptide residue consisting of DGGFG (SEQ ID NO: 10), DGGF (SEQ ID NO: 9), KGGFG (SEQ ID NO: 15), EGGFG (SEQ ID NO: 16), DDGGFG (SEQ ID NO: 13), KDGGFG (SEQ ID NO: 14), SGGFG (SEQ ID NO: 17), D d GGFG, DGGFS (SEQ ID NO: 12), GGFGS (SEQ ID NO: 5), GGFGGE (SEQ ID NO: 7), or DG Me GFG (SEQ ID NO: 11), wherein superscript of d indicates that the amino acid is in a D-form, and superscript of Me indicates that the amino acid is N-methylated at its α-amino group,
-(Succinimid-3-yl-N)— has a structure represented by the following formula:
which is connected to the antibody at position 3 thereof and is connected to the methylene group in the linker structure containing this structure on the nitrogen atom at position 1.
2. The antibody-drug conjugate according to claim 1 , wherein L P is DGGFG (SEQ ID NO: 10), D d GGFG, or DG Me GFG (SEQ ID NO: 11).
3. The antibody-drug conjugate according to claim 1 , wherein the average number of units of the antitumor compound conjugated per antibody molecule is in the range of from 1 to 8.
4. The antibody-drug conjugate according to claim 1 , wherein the average number of units of the antitumor compound conjugated per antibody molecule is in the range of from 3 to 8.
5. A drug containing the antibody-drug conjugate according to claim 1 , a salt thereof, or a hydrate thereof.
6. An antitumor drug and/or anticancer drug containing the antibody-drug conjugate according to claim 1 , a salt thereof, or a hydrate thereof.
7. A pharmaceutical composition containing the antibody-drug conjugate according to claim 1 , a salt thereof, or a hydrate thereof as an active component, and a pharmaceutically acceptable formulation component.
8. The antibody-drug conjugate according to claim 1 , wherein the drug-linker structure moiety, in which a drug is connected to -L 1 -L 2 -L P -, is one drug-linker structure selected from the following group:
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-DGGFG (SEQ ID NO: 10)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)—KGGFG (SEQ ID NO: 15)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-DGGFG (SEQ ID NO: 10)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 —C(═O)-DGGFG (SEQ ID NO: 10)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —C(═O)-DGGFG (SEQ ID NO: 10)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)—NH—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —C(═O)-DGGFG (SEQ ID NO: 10)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)—SGGFG (SEQ ID NO: 17)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-D d GGFG-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-EGGFG (SEQ ID NO: 16)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-DGGFS (SEQ ID NO: 12)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFGS (SEQ ID NO: 5)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 —C(═O)-GGFGGE (SEQ ID NO: 7)-(NH-DX),
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-GGFGGE (SEQ ID NO: 7)-(NH-DX), or
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-DG Me GFG (SEQ ID NO: 11)-(NH-DX),
wherein (NH-DX) is a group represented by the following formula:
wherein the nitrogen atom of the amino group at position 1 is the connecting position.
9. The antibody-drug conjugate according to claim 1 , wherein the drug-linker structure moiety, in which a drug is connected to L 1 -L 2 -L P - is
-(Succinimid-3-yl-N)—CH 2 CH 2 CH 2 CH 2 CH 2 —C(═O)-DGGFG(SEQ ID NO: 10)-(NH-DX)
wherein (NH-DX) is a group represented by the following formula:
wherein the nitrogen atom of the amino group at position 1 is the connecting position.
10. A method for treating a HER2 expressing tumor and/or cancer comprising administering the antibody-drug conjugate according to claim 1 , a salt thereof, or a hydrate thereof.
11. The treatment method according to claim 10 which is for use against lung cancer, urothelial cancer, colorectal cancer, prostate cancer, ovarian cancer, pancreatic cancer, breast cancer, bladder cancer, gastric cancer, gastrointestinal stromal tumor, uterine cervix cancer, esophageal cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular cancer, colon cancer, rectal cancer, endometrial cancer, uterine cancer, salivary gland cancer, kidney cancer, vulval cancer, penis cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, or sarcoma.